Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318617 · ClinicalTrials.gov registry record
Effect Of GW501516X On How The Heart Obtains And Uses Energy
A clinical trial, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- 30
- Enrollment target
NCT00318617: Clinical Trial study, sponsored by GlaxoSmithKline.
NCT00318617 is a clinical trial that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00318617 was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, including levels of certain lipids (fats) and proteins in your blood. The data from this study may help researchers better understand the actions of this drug in the body and if this drug may be useful to treat patients with heart disease.
Interventions
- DRUG GW510516X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-12 |
Why NCT00318617 stopped before completion
NCT00318617 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which GW510516X is the first listed.
NCT00318617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00318617 about?
NCT00318617 is a clinical study titled "Effect Of GW501516X On How The Heart Obtains And Uses Energy". The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, ...
What is the current status of trial NCT00318617?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2005-12.
What interventions are being tested in trial NCT00318617?
The interventions under investigation include: GW510516X (DRUG).
Who is sponsoring clinical trial NCT00318617?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia